Ramucirumab and Carbo-Paclitaxel for Untreated Thymic Carcinoma / B3 Thymoma With Carcinoma (RELEVENT)
NCT03921671
·
clinicaltrials.gov ↗
PHASE2
Phase
UNKNOWN
Status
60
Enrollment
OTHER
Sponsor class
Conditions
Thymic Carcinoma
Thymoma
Interventions
COMBINATION_PRODUCT:
Ramucirumab
Sponsor
Claudia Proto